Proteome analysis of the sera from Chinese Parkinson's disease patients

Neuroscience Letters

Volumn 479, Issue 2, 2010, Pages 175-179

  Zhao, Xin ^a,c   Xiao, Wei Zhong ^b   Pu, Xiao Ping ^a,c   Zhong, Li Jun ^a  

^a PEKING UNIVERSITY   (China)

^b PEKING UNIVERSITY THIRD HOSPITAL   (China)

^c PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

2 DE; Biomarker; Parkinson's disease; Proteomics; Serum

Indexed keywords

ALPHA 1 MICROGLOBULIN; ALPHA2 GLYCOPROTEIN; BETA2 GLYCOPROTEIN 1; BIOLOGICAL MARKER; CLUSTERIN; COMPLEX FORMING GLYCOPROTEIN HC; HAPTOGLOBIN; IMMUNOGLOBULIN GAMMA 3 CHAIN C REGION; IMMUNOGLOBULIN KAPPA CHAIN; MYOSIN HEAVY CHAIN; PREALBUMIN; PROTEIN DYNC1H1; PROTEIN KIAA0325; PROTEOME; SERUM AMYLOID A; UNCLASSIFIED DRUG; PLASMA PROTEIN;

AGED; ANTIOXIDANT ACTIVITY; ARTICLE; CELL PROLIFERATION; CELL TRANSPORT; CHINESE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DOWN REGULATION; FEMALE; HUMAN; IMMUNOREGULATION; LIPID METABOLISM; MALE; MASS SPECTROMETRY; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEOMICS; TWO DIMENSIONAL GEL ELECTROPHORESIS; UPREGULATION; WESTERN BLOTTING; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; CHINA; METABOLISM; MIDDLE AGED;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MARKERS; BLOOD PROTEINS; CHINA; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; PROTEOME;

EID: 77953916957     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2010.05.063     Document Type: Article

References (28)

1. Basso M., Giraudo S., Corpillo D., Bergamasco B., Lopiano L., Fasano M. Proteome analysis of human substantia nigra in Parkinson's disease. Proteomics 2004, 4:3943-3952.
2. Calne D.B., Snow B.J., Lee C. Criteria for diagnosing Parkinson's disease. Ann. Neurol. 1992, 32(Suppl.):S125-S127.
3. Chen Y.Y., Lin S.Y., Yeh Y.Y., Hsiao H.H., Wu C.Y., Chen S.T., Wang A.H. A modified protein precipitation procedure for efficient removal of albumin from serum. Electrophoresis 2005, 26:2117-2127.
4. Choi J., Levey A.I., Weintraub S.T., Rees H.D., Gearing M., Chin L.S., Li L. Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases. J. Biol. Chem. 2004, 279:13256-13264.
5. Connors L.H., Lim A., Prokaeva T., Roskens V.A., Costello C.E. Tabulation of human transthyretin (TTR) variants, 2003. Amyloid 2003, 10:160-184.
6. Costa-Mallen P., Checkoway H., Zabeti A., Edenfield M.J., Swanson P.D., Longstreth W.T., Franklin G.M., Smith-Weller T., Sadrzadeh S.M. The functional polymorphism of the hemoglobin-binding protein haptoglobin influences susceptibility to idiopathic Parkinson's disease. Am. J. Med. Genet. B: Neuropsychiatr. Genet. 2008, 147B:216-222.
7. De Iuliis A., Grigoletto J., Recchia A., Giusti P., Arslan P. A proteomic approach in the study of an animal model of Parkinson's disease. Clin. Chim. Acta 2005, 357:202-209.
8. De Roos B., Geelen A., Ross K., Rucklidge G., Reid M., Duncan G., Caslake M., Horgan G., Brouwer I.A. Identification of potential serum biomarkers of inflammation and lipid modulation that are altered by fish oil supplementation in healthy volunteers. Proteomics 2008, 8:1965-1974.
9. Deluca G.C., Ebers G.C., Esiri M.M. The extent of axonal loss in the long tracts in hereditary spastic paraplegia. Neuropathol. Appl. Neurobiol. 2004, 30:576-584.
10. Hafezparast M., Klocke R., Ruhrberg C., Marquardt A., Ahmad-Annuar A., Bowen S., Lalli G., Witherden A.S., Hummerich H., Nicholson S., Morgan P.J., Oozageer R., Priestley J.V., Averill S., King V.R., Ball S., Peters J., Toda T., Yamamoto A., Hiraoka Y., Augustin M., Korthaus D., Wattler S., Wabnitz P., Dickneite C., Lampel S., Boehme F., Peraus G., Popp A., Rudelius M., Schlegel J., Fuchs H., Hrabe de Angelis M., Schiavo G., Shima D.T., Russ A.P., Stumm G., Martin J.E., Fisher E.M. Mutations in dynein link motor neuron degeneration to defects in retrograde transport. Science 2003, 300:808-812.
11. Hoehn M.M., Yahr M.D. Parkinsonism: onset, progression and mortality. Neurology 1967, 17:427-442.
12. Holloway K.V., O'Gorman M., Woods P., Morton J.P., Evans L., Cable N.T., Goldspink D.F., Burniston J.G. Proteomic investigation of changes in human vastus lateralis muscle in response to interval-exercise training. Proteomics 2009, 9:5155-5174.
13. Hughes A.J., Daniel S.E., Kilford L., Lees A.J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry 1992, 55:181-184.
14. Inagaki T., Shikimi T., Matsubara K., Kobayashi S., Ishino H., Okunishi H., Takaori S. Non-existence of a positive correlation between urinary levels of alpha 1-microglobulin and ulinastatin in patients with Parkinson's disease. Psychiatry Clin. Neurosci. 1996, 50:231-233.
15. James P.A., Talbot K. The molecular genetics of non-ALS motor neuron diseases. Biochim. Biophys. Acta 2006, 1762:986-1000.
16. Kaku K., Shikimi T., Inagaki T., Ishino H., Okunishi H., Takaori S. Impairment of the correlation between urinary contents of alpha-1-microglobulin and ulinastatin is induced by intracerebroventricularly administered interleukin-6 in mice. Neuropsychobiology 1999, 40:33-39.
17. Langen H., Roder D., Juranville J.F., Fountoulakis M. Effect of protein application mode and acrylamide concentration on the resolution of protein spots separated by two-dimensional gel electrophoresis. Electrophoresis 1997, 18:2085-2090.
18. McGeer P.L., Itagaki S., Akiyama H., McGeer E.G. Rate of cell death in parkinsonism indicates active neuropathological process. Ann. Neurol. 1988, 24:574-576.
19. McNaught K.S., Olanow C.W., Halliwell B., Isacson O., Jenner P. Failure of the ubiquitin-proteasome system in Parkinson's disease. Nat. Rev. Neurosci. 2001, 2:589-594.
20. Owen A.D., Schapira A.H., Jenner P., Marsden C.D. Oxidative stress and Parkinson's disease. Ann. N. Y. Acad. Sci. 1996, 786:217-223.
21. Rajput A.H., Rozdilsky B., Rajput A. Accuracy of clinical diagnosis in parkinsonism-a prospective study. Can. J. Neurol. Sci. 1991, 18:275-278.
22. Rodrĺguez C.E., Arranz J.A., Colomeè N., Bech-Serra J.J., Canals F., Toro M.D., Encarnaciò RiudorGuo J. Proteomic analysis in cerebrospinal fluid of patients with atypical nonketotic hyperglycinemia and pulmonary hypertension-a pilot study. Proteomics Clin. Appl. 2009, 3:1430-1439.
23. Santos S.D., Fernandes R., Saraiva M.J. The heat shock response modulates transthyretin deposition in the peripheral and autonomic nervous systems. Neurobiol. Aging 2010, 31:280-289.
24. Sasaki K., Doh-ura K., Wakisaka Y., Iwaki T. Clusterin/apolipoprotein J is associated with cortical Lewy bodies: immunohistochemical study in cases with alpha-synucleinopathies. Acta Neuropathol 2002, 104:225-230.
25. Shikimi T., Inagaki T., Kaku K., Ishino H., Okunishi H., Takaori S. Nullification of a positive correlation between urinary levels of alpha 1-microglobulin and ulinastatin by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mice. Psychoneuroendocrinology 1997, 22:269-275.
26. Sinha A., Srivastava N., Singh S., Singh A.K., Bhushan S., Shukla R., Singh M.P. Identification of differentially displayed proteins in cerebrospinal fluid of Parkinson's disease patients: a proteomic approach. Clin. Chim. Acta 2009, 400:14-20.
27. Sizova D., Charbaut E., Delalande F., Poirier F., High A.A., Parker F., Van Dorsselaer A., Duchesne M., Diu-Hercend A. Proteomic analysis of brain tissue from an Alzheimer's disease mouse model by two-dimensional difference gel electrophoresis. Neurobiol. Aging 2007, 28:357-370.
28. Thomas B., Beal M.F. Parkinson's disease. Hum. Mol. Genet. 2007, 16(Spec No. 2):R183-R194.